A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 30, 2024

Conditions

IgA NephropathyFocal Segmental Glomerulosclerosis

Interventions

DRUG

HS-10390 tablet

Oral administration of specified dose of HS-10390

DRUG

Placebo tablet

Oral administration of matching dose ofplacebo

Trial Locations (1)

RECRUITING

Zhongda Hospital, Affiliated to Southeast University, Nanjing

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY